ENTX — Entera Bio Ltd.

Is ENTX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of August 19, 2026

Entera Bio Ltd. (ENTX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $2.89. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

Entera Bio Ltd. (ENTX) is a clinical-stage company focused on oral delivery of peptide therapeutics. The firm’s platform addresses meaningful commercial opportunity if clinical efficacy and scalable manufacturing are demonstrated. Near-term upside depends on positive clinical readouts, partnering/licensing events, or clear evidence of a viable commercial pathway; downside is driven by typical biotech risks: trial setbacks, financing needs, and competitive/technical hurdles. Public information and social sentiment are limited, making the share price sensitive to news flow and financing activity. In the current macro tone, modest appetite for growth biotech exists, but company-specific execution and balance-sheet clarity will determine directional outcomes.

Key factors

  • Oral peptide delivery platform that addresses a sizable addressable market for injectable peptides and biologics
  • Clinical-stage pipeline with potential near- to mid-term catalysts (trial readouts or regulatory interactions) that could re-rate the stock
  • Sector thematic tailwinds for biologics and peptide demand (CDMO/CRO expansion and interest in non-injectable formulations)
  • Limited recent public-company disclosures and thin liquidity increase sensitivity to news and funding developments
  • Macro environment showing cautious risk-on tone which can support small-cap biotech risk appetite in the near term
  • Potential partnership or licensing interest given the platform’s utility for converting injectables to oral forms

Risks

  • Clinical or regulatory failure for lead programs, which would materially reduce upside
  • Cash runway uncertainty and likely need for dilutive financing absent a partnering or licensing deal
  • Manufacturing, formulation or bioavailability challenges specific to oral peptide delivery at scale
  • Strong incumbent competition from established peptide/biologic developers, plus alternative delivery technologies
  • Low social/media visibility and limited analyst coverage, increasing volatility and information asymmetry
  • Adverse policy or payer dynamics that could affect commercial adoption or reimbursement for converted therapies

See today's live rating, score and targets

Members see the live hourly rating for ENTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.